Aclaris Therapeutics, Inc. <ACRS.O>: Canaccord Genuity initiates coverage with Buy rating; target price $10
ACRS•Related News
US urges hands-off approach to AI regulation at G20 tech meeting
QQQ•
Chaince Digital files Form 3 initial beneficial ownership statement for director Li Jialin
CD•
Nasdaq trade halt continues <UCFI.O> reason not available at 11:12 AM
UCFI•
Lument CEO James Flynn elected chair of Fannie Mae Multifamily DUS Advisory Council
LFT•
Tesla new car sales in Italy down 35.8% year-on-year in August
TSLA•